Compound Semaglutide Ban: What Changed and What Comes Next

The compound semaglutide ban is the FDA's decision to stop pharmacies from making their own copies of Ozempic, Wegovy, and Rybelsus. It followed the agency's February 21, 2025 declaration that the semaglutide shortage was over, and it gave compounding pharmacies until May 22, 2025 to stop producing "essentially a copy" versions of the drug. Compounded semaglutide is not FDA-approved, and for most patients the legal pathway to it has now closed.

This article explains what changed, what is still allowed, and what to do if you were getting semaglutide from a compounding pharmacy.

What the FDA Ban on Compounded Semaglutide Actually Says

Federal law lets compounding pharmacies prepare copies of a brand-name drug only while that drug appears on the FDA's shortage list. That exemption is what made compounded semaglutide so widely available between 2022 and early 2025.

When the shortage ended, the exemption ended with it. A compounded drug that is "essentially a copy" of an FDA-approved product generally cannot be made and distributed under either section 503A (traditional compounding pharmacies) or section 503B (outsourcing facilities).

Tirzepatide (Mounjaro, Zepbound) went through the same process a few months earlier. Patients often ask what is the difference between semaglutide and tirzepatide compound products, and the practical answer is that both are now off-limits to large-scale compounding.

Why the FDA Ended Compounded GLP-1 Copies

• Supply recovered. Novo Nordisk showed it could meet national demand for Ozempic, Wegovy, and Rybelsus.
• Safety reports piled up. FDA received hundreds of adverse event reports tied to compounded semaglutide, including dosing errors that led to hospitalizations.
• Legal exposure. Novo Nordisk sued multiple compounding pharmacies and clinics, arguing that copycat products infringed its patents and confused patients.

Regulators also objected to compounded versions built on semaglutide sodium or semaglutide acetate, which are different chemical forms than the semaglutide base used in approved products.

What Is Still Legal After the Ban

Compounding semaglutide is not banned outright. A 503A pharmacy can still prepare semaglutide for a specific patient when a prescriber documents a real clinical need the approved product cannot meet, such as a documented allergy to an inactive ingredient or a dosage form the patient cannot use.

The word "documented" carries the weight here. FDA has made clear that tweaking a formula purely to make it look different does not create a legal exemption. That is why products marketed as semaglutide l carnitine blends drew scrutiny: adding an ingredient for marketing purposes does not turn an essentially-a-copy drug into a lawful compounded one.

In practice, this means:

• Large-scale production of compounded semaglutide has stopped.
• Patient-specific compounding remains possible in narrow, well-documented cases.
• Selling compounded semaglutide from a standing inventory is not permitted.

How Safe Is Compounded Semaglutide?

Questions about compound semaglutide safe use are fair, and the honest answer is that risk depends heavily on the source. Compounded drugs are not reviewed by FDA for safety, effectiveness, or quality the way Ozempic, Wegovy, and Rybelsus are.

Documented problems with compounded GLP-1s include:

• Dosing errors. Reported compound semaglutide doses have varied widely, and patients have been told to draw "units" from a vial without understanding how many milligrams that delivers.
• Potency problems. Independent testing has found samples that were weaker or stronger than the label stated.
• Wrong active ingredient. Some products contained semaglutide sodium rather than semaglutide base.
• Sterility lapses. A handful of compounders have faced recalls and state board actions.

None of this means every compounded product was bad. It does mean that two vials labeled the same way could contain very different things.

What to Do If Your Compounded Semaglutide Is Gone

1. Talk to your prescriber before you stop. Abruptly halting a GLP-1 can bring back appetite changes and blood sugar swings, and your clinician may need to adjust other medications.
2. Ask about brand-name semaglutide. Wegovy is approved for weight management, while Ozempic and Rybelsus are approved for type 2 diabetes. Insurance coverage and prior authorization rules vary widely.
3. Look into cash-pay programs. Manufacturers now sell brand-name semaglutide at reduced cash prices through their own pharmacies, which is often cheaper than a compounded product was.
4. Be wary of "research use only" vials. Legitimate pharmacies do not sell injectable drugs labeled for laboratory research. Products sold that way are not inspected, and their sterility is not guaranteed.
5. Report problems. Side effects or suspected fake products can be reported to FDA's MedWatch program.

The Gray Market After the Ban

When a legal supply channel closes, gray markets expand. Websites still advertise semaglutide "for research purposes," often bundled with other unapproved peptides sold under the same disclaimer.

Some of those products include investigational compounds approved for no human use at all. A late-stage trial program combines cagrilintide and semaglutide into one weekly injection known as CagriSema, but that combination is still being studied and is not available by prescription. Buying it from a peptide vendor means injecting a substance with no independent verification of identity, dose, or sterility.

Price is another warning sign. If a seller offers semaglutide at a fraction of the pharmacy price with no prescription and no pharmacist involved, the product is not being made under the conditions that make compounded drugs safe to inject.

The Bottom Line

The compound semaglutide ban did not remove semaglutide from the market; it removed a large, lightly regulated supply channel. Brand-name semaglutide remains available with a prescription, and compounding still exists for narrow, patient-specific situations.

If you were using compounded semaglutide, the safest next step is a conversation with a licensed healthcare professional who can review your dose, your insurance options, and the risks of switching products.